ExpreS2ion Biotech Holding AB
STO:EXPRS2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
ExpreS2ion Biotech Holding AB
STO:EXPRS2
|
SE |
|
P
|
PetroChina Co Ltd
XBER:PC6
|
CN |
|
B
|
Biome Australia Ltd
ASX:BIO
|
AU |
|
Bantec Inc
OTC:BANT
|
US |
|
Lepanto Consolidated Mining Co
OTC:LECBF
|
PH |
|
Steel Partners Holdings LP
NYSE:SPLP
|
US |
|
Digital Core REIT
SGX:DCRU
|
SG |
|
Rumble Inc
NASDAQ:RUM
|
US |
|
Liberty Media Corp
OTC:LLYVB
|
US |
|
Vesuvius PLC
LSE:VSVS
|
UK |
|
Wheels Up Experience Inc
NYSE:UP
|
US |
Wall St Price Targets
EXPRS2 Price Targets Summary
ExpreS2ion Biotech Holding AB
According to Wall Street analysts, the average 1-year price target for EXPRS2 is 6.12 SEK with a low forecast of 6.06 SEK and a high forecast of 6.3 SEK.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is EXPRS2's stock price target?
Price Target
6.12
SEK
According to Wall Street analysts, the average 1-year price target for EXPRS2 is 6.12 SEK with a low forecast of 6.06 SEK and a high forecast of 6.3 SEK.
What is the Revenue forecast for ExpreS2ion Biotech Holding AB?
Projected CAGR
39%
The compound annual growth rate for Revenue over the next 3 years is 39%.